Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Steven Wayne Goldstein is active.

Publication


Featured researches published by Steven Wayne Goldstein.


Bioorganic & Medicinal Chemistry Letters | 2009

Tetrahydroquinoline derivatives as CRTH2 antagonists

Mohamed M. A. Awad; Marc Bazin; Frederic Feru; Steven Wayne Goldstein; Cyrille Kuhn

A series of tetrahydroquinoline-derived inhibitors of the CRTH2 receptor was discovered by a high throughput screen. Optimization of these compounds for potency and pharmacokinetic properties led to the discovery of potent and orally bioavailable CRTH2 antagonists.


Bioorganic & Medicinal Chemistry Letters | 1992

CP-99,711: a non-peptide glucagon receptor antagonist

Judith L. Collins; Paul J. Dambek; Steven Wayne Goldstein; W. Stephen Faraci

Abstract CP-99,711, identified in a screening program, displaces [125I]-glucagon from its rat liver receptor. We describe here the synthesis of this compound and its characterization as a functional glucagon receptor antagonist.


Journal of Medicinal Chemistry | 2012

Discovery and Optimization of a Novel Spiropyrrolidine Inhibitor of β-Secretase (BACE1) through Fragment-Based Drug Design

Ivan Viktorovich Efremov; Felix Vajdos; Kris A. Borzilleri; Steven Capetta; Hou Chen; Peter Hans Dorff; Jason K. Dutra; Steven Wayne Goldstein; Mahmoud N. Mansour; Alexander S. McColl; Stephen Noell; Christine E. Oborski; Thomas N. O’Connell; Theresa J. O’Sullivan; Jayvardhan Pandit; Hong Wang; BinQing Wei; Jane M. Withka

The aspartyl protease β-secretase, or BACE, has been demonstrated to be a key factor in the proteolytic formation of Aβ-peptide, a major component of plaques in the brains of Alzheimers disease (AD) patients, and inhibition of this enzyme has emerged as a major strategy for pharmacologic intervention in AD. An X-ray-based fragment screen of Pfizers proprietary fragment collection has resulted in the identification of a novel BACE binder featuring spiropyrrolidine framework. Although exhibiting only weak inhibitory activity against the BACE enzyme, the small compound was verified by biophysical and NMR-based methods as a bona fide BACE inhibitor. Subsequent optimization of the lead compound, relying heavily on structure-based drug design and computational prediction of physiochemical properties, resulted in a nearly 1000-fold improvement in potency while maintaining ligand efficiency and properties predictive of good permeability and low P-gp liability.


Tetrahedron Letters | 1998

Solid phase synthesis of phosphinopeptoids as transition state analog inhibitors

Peter Hans Dorff; Gordon Chiu; Steven Wayne Goldstein; Bradley Paul Morgan

Abstract A procedure for preparing novel phosphinopeptoids, 1 , on a solid support is described. The key step in the synthesis includes a conjugate addition of the trivalent form of a protected aminomethylphosphinic acid ( 5 ) to a resin-bound acrylate.


Tetrahedron Letters | 1991

α-Azido acids in heterocyclic synthesis

Steven Wayne Goldstein; Ruth E. McDermott; Michael Raymond Groton Makowski; Cynthia Eller

Abstract 2-Aminobenzophenones and acetophenones were N-acylated with α-azido carboxylic acids to give the corresponding anilides. Reductive cyclization provided 3-substituted-2H-1,4-benzodiazepin-2-ones in good (46–99%) yields.


Archive | 1991

Benzylphosphonic acid tyrosine kinase inhibitors

Robert L. Dow; Steven Wayne Goldstein


Archive | 1989

Thiazolidinedione hypoglycemic agents

David Alan Clark; Steven Wayne Goldstein; Gerald F. Holland; Bernard Hulin; James P. Rizzi


Archive | 1989

Hypoglycemic thiazolidinedione derivatives

David Alan Clark; Bernard Hulin; Steven Wayne Goldstein


Journal of Medicinal Chemistry | 1992

Novel thiazolidine-2,4-diones as potent euglycemic agents

Bernard Hulin; David Alan Clark; Steven Wayne Goldstein; Ruth E. McDermott; Paul J. Dambek; Werner H. Kappeler; Charles H. Lamphere; Diana M. Lewis; James P. Rizzi


Journal of Medicinal Chemistry | 1991

Substituted dihydrobenzopyran and dihydrobenzofuran thiazolidine-2,4-diones as hypoglycemic agents.

David Alan Clark; Steven Wayne Goldstein; Robert A. Volkmann; James Frederick Eggler; Gerald F. Holland; Bernard Hulin; Ralph W. Stevenson; Kreutter Dk; Gibbs Em; Krupp Mn

Collaboration


Dive into the Steven Wayne Goldstein's collaboration.

Researchain Logo
Decentralizing Knowledge